Tradestie Institutional Equity Comparison Engine
AKRO vs MTVA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AKRO Overall Edge
AKRO Captures Institutional Edge (3โ0 Pillars ยท 5โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MTVA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against MTVA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
AKRO N/M vs MTVA N/M Fwd P/E
Growth & Margin Winner
AKRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
AKRO
1Y +76.8% vs +32.2% ยท 52W Pos 90% vs 4%
Options & Structure Winner
AKRO
UNCLASSIFIED (30th %ile IV) vs UNCLASSIFIED (N/A IV)
AKRO
NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap
$4.5B
1M Return
+1.37%
1Y Return
+76.75%
Forward P/E
N/M
Unified AI Score
60.0 / 100
BUY
Tech 55.0
Fund 52.0
Flow 50.0
Mom 50.0
MTVA
NASDAQ
MetaVia Inc. Common Stock
Pharmaceutical Preparations
$1.01
-5.61% 1D
Market Cap
$7.2M
1M Return
-27.34%
1Y Return
+32.2%
Forward P/E
N/M
Unified AI Score
48.0 / 100
HOLD
Tech 40.0
Fund 60.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AKRO +76.75%
MTVA +32.2%
Spread: +1407.28 pp (MTVA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AKRO TTM Op. Margin: 0.0%
MTVA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs MTVA. Trailing 12-month operating profitability (AKRO 0.0% vs MTVA 0.0%) and valuation multiples (AKRO N/M vs MTVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AKRO | MTVA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.5B | $7.2M | Larger Scale | AKRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -175.7% | Higher ROE | AKRO |
| 52-Week Range Position Momentum | 90% ($21โ$58) | 4% ($1โ$13) | Stronger Trend | AKRO |
| Beta / 30D Volatility Risk Regime | 0.90ฮฒ ยท 2% Vol | 1.30ฮฒ ยท 166% Vol | Lower Realized Risk | AKRO |
| Unified Institutional Score Composite Signal | 60.0 / 100 (BUY) | 48.0 / 100 (HOLD) | Higher Composite | AKRO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AKRO vs MTVA Buy Guide
AKRO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
30th %ile
IV Regime
Balanced (25thโ60th %ile)
MTVA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AKRO nor MTVA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.